about
Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection.Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.Treatment of hepatitis C with new fixed dose combinations.(-)-Epigallocatechin-3-gallate enhances poly I:C-induced interferon-λ1 production and inhibits hepatitis C virus replication in hepatocytes.ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients.Long Non-coding RNAs in Hepatitis C Virus-Infected Cells.Chronic hepatitis C liver microenvironment: role of the Th17/Treg interplay related to fibrogenesis.Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies.According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1low HCV-Specific CD8+ Cell Reactivity.NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities.Karyopherin alpha6 Is Required for the Replication of Porcine Reproductive and Respiratory Syndrome Virus and Zika Virus.Observations on the launch of new drugs for hepatitis C.Regulation of the Interferon Response by lncRNAs in HCV Infection.Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients.Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Interaction of viral oncogenic proteins with the Wnt signaling pathwayOncogenic Signaling Induced by HCV InfectionThe Frequency of Hepatitis C and its Risk Factors Among Health Care Providers at Tehsil Headquarter Hospital, Hasilpur, PakistanNovel methods to prevent HCV transmission
P2860
Q40080477-66D8D5DB-85DB-4E51-B27E-2E1194212355Q40082368-013FF92A-2CE7-404F-9BD5-E2BBC57D6D99Q40104295-0129F5CB-3DA2-49B1-A9DE-4D0C88934B8CQ40148071-EDCF38C4-6759-4BDC-AC8D-A974D11EE89EQ41608489-FF34D00F-7DA1-4FAF-B0A8-DB843E2DB446Q41919708-1EAED489-FEC6-457E-A373-67509CA6F88CQ42369135-5B3C520F-A68D-4CC8-B470-840FDF592DD4Q42378927-249ECA21-28CE-49E0-8FEB-D0CBDBDA811FQ47098282-5C454010-AFCB-4AF3-B12C-8BAA1C612F9DQ47593614-B0FE26B3-9494-4B67-8B82-431DD881595FQ50133220-2FA2AFC3-DC51-4CEF-8984-2C79C8EA4035Q51336841-E706B71D-67F1-4F5B-AFFD-375D4F718294Q52673114-374A3797-9AD1-4F89-83F7-869C5FB2AD74Q55122208-14510D02-A36E-4366-A361-FB1F09221A39Q55191989-A41B33A1-6844-4605-9FEE-D68EC1569BF2Q55256500-AD526023-7CFB-4415-B1C7-08574A766CDDQ55280981-AF53FF99-8BAB-466A-8B49-712B83F19C14Q56476000-06CDF8D7-9447-4066-AF24-9D5E51BCA322Q57050806-276D0487-D920-4D7A-B5AC-4D4F6CD794F0Q57823686-794B0BF8-4170-4EFD-AD6E-601C03F54A79Q58439383-EB0BE807-0749-4A98-B750-3151D8D94BE6
P2860
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Hepatitis C virus infection.
@ast
Hepatitis C virus infection.
@en
type
label
Hepatitis C virus infection.
@ast
Hepatitis C virus infection.
@en
prefLabel
Hepatitis C virus infection.
@ast
Hepatitis C virus infection.
@en
P2093
P2860
P356
P1476
Hepatitis C virus infection.
@en
P2093
Maria Buti
Michael P Manns
Norah Terrault
Zobair Younossi
P2860
P2888
P356
10.1038/NRDP.2017.6
P577
2017-03-02T00:00:00Z
P6179
1084129659